|
Charles
O. Rutledge, Ph.D.
Vice President for
Research
Phone: (765) 494-6209;
Fax: (765) 496-2589
E-mail: chipr@purdue.edu
Charles
O. (Chip) Rutledge,
Vice President for
Research at Purdue University,
received a B.S. Pharmacy
at the University of Kansas
in 1959 and a Ph.D. in
Pharmacology at Harvard
in 1966. He was a NATO
Postdoctoral Fellow in
Pharmacology in Gothenburg,
Sweden, and was on the
faculty in the Department
of Pharmacology at the
University of Colorado
School of Medicine from
1967 to 1975. Dr. Rutledge
was then appointed Chairman
of the Department of Pharmacology
and Toxicology at the University
of Kansas School of Pharmacy.
In 1987, Dr. Rutledge was
appointed Dean of the Schools
of Pharmacy, Nursing, and
Health Sciences at Purdue
and served in this capacity
until 2002. In 2001, he
was appointed Executive
Director for Discovery
Park, a new 126 million
dollar interdisciplinary
research initiative on
the Purdue campus.
Dr. Rutledge
has been very active in
the American Association
of Colleges of Pharmacy,
serving as Chair of the
Council of Faculties, Chair
of the Council of Deans,
and Association President
in 1996-97. He has also
served on the Volwiler
Award Committee, the Research
and Graduate Affairs Committee,
the Committee on the Present
and Future Needs of the
Council of Faculties, the
Academic Management System
Organizing Committee, and
was a member of the Commission
on Implementing Change
in Pharmacy Education.
Dr. Rutledge is a registered
pharmacist in Kansas and
Indiana. He served as the
first Chair of the Indiana
Drug Utilization Review
Board.
Dr. Rutledge
served as President of
the American Society for
Pharmacology and Experimental
Therapeutics from 1996-97.
He has served as Councilor
and Treasurer of this organization.
He currently is the Chairman
of the Investment Subcommittee
of the Finance Committee.
His interest in financial
affairs was also demonstrated
when he served as Treasurer
of the Federation of American
Societies for Experimental
Biology from 1994-96. He
was Field Editor for the
Journal of Pharmacology
and Experimental Therapeutics
and Editor of Biogenic
Amines. Dr. Rutledge has
been a member of two NIMH
Review Committees and the
NIGMS Pharmacological Sciences
Review Committee, which
reviews training grants
in the pharmacological
sciences.
Dr. Rutledge
has published over 150
papers and abstracts in
the field of neuropharmacology.
His research includes establishment
of a model for studying
the mechanism by which
amphetamine releases biogenic
amine neurotransmitters
from nerve endings. He
has also conducted studies
on the biochemical-behavioral
correlates in the use of
levodopa for the treatment
of Parkinsonism. Other
studies have involved an
examination of the lipid
micro-environment of nerve
endings as a determinant
of the activity of proteins
involved in neurotransmission.
Presentations:
The Endless Frontier in Science and Technology |
